COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 34 FDA records to the applicant name Medtronic MiniMed, Inc.. The collection includes 3 510(k) clearances. It includes 2 original PMA approvals. 10 entries are PMA supplements. 19 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 28, 2016 to Sep 29, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code OZP appears in 19 of the 34 linked filings. The collection spans 4 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P160017, with 19 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 18000 Devonshire St., Northridge, CA, 91325. Recorded on P160017/S140, decision dated Sep 29, 2026.
Device categories in this collection
Automated Insulin Dosing Device System, Single Hormonal Control; Sensor, Glucose, Invasive, Component of automated insulin delivery system; Alternate Controller Enabled Insulin Infusion Pump; Interoperable Automated Glycemic Controller.
Changes described in PMA records
The FDA record for P160017/S140 shows approval of a revised protocol for the post-approval study of the MiniMed 780G System, a Medtronic Minimed automated insulin dosing device system with single hormonal control under product code OZP. The supplement was filed on the Normal 180 Day Track No User Fee, with the stated supplement reason "Postapproval Study Protocol." The entry describes a protocol change, not a new approval of the whole system; S140 is a supplement to the original P160017 PMA rather than an original decision in its own right.
The database entry does not specify which protocol elements were revised, nor does it report study size, endpoints, timelines or results. The reported purpose is the revised post-approval study protocol, and this record is not independent proof of safety or clinical effectiveness. How the revision relates to the original PMA's scope cannot be determined from the supplied fields beyond the supplement identifier.
FDA approval-order wording
Approval of the revised protocol for the post-approval study (PAS)
Sep 29, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: to qualify an additional supplier of electronic stacks and printed circuit boards, subcomponents of the MiniMed 770G, and MiniMed 780G systems
Aug 5, 2026 · 30-Day NoticeFDA’s recorded scope: undefined
Jul 21, 2026 · 30-Day NoticeFDA’s recorded scope: undefined
Jul 21, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for updating the sensor compressor dimensions in the Synergy Sensor (Simplera) assembly.
Jun 12, 2026 · Real-Time ProcessSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.